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1. Introduction 
Covalently interacting drugs may form long-lived ties, 
therefore irreversible inhibitors may provide unique benefits with 
respect to target occupancy beyond metabolic half-life and 
kinetic selectivity.
1–5
 Often, an active site residue in a crucial 
enzyme is covalently modified by an electrophilic trap, 
frequently termed a ‘warhead’.
4
 We have previously 
demonstrated that a new warhead can be successfully explored 
and further developed by drawing inspiration from relatively 
simple reactive organic compounds such as the sulfonyl fluoride 
moiety in phenylmethane sulfonyl fluoride (PMSF).
5
 This 
previous work led to the incorporation of the sulfonyl fluoride 
moiety in (functionalized) peptides leading to powerful peptido 
sulfonyl fluoride proteasome inhibitors and prolyl oligopeptidase 
(POP) inhibitors.
6–9
 The sulfonyl fluoride warhead in proteasome 
inhibitors exhibited a unique cross linking mechanism, 
highlighting the potential of relatively simple reactive moieties.
7,8
 
This sulfonyl fluoride warhead reacted preferentially with serine 
and threonine hydroxyl groups. However, from the realm of 
sulfur compounds and sulfur chemistry we wish to introduce here 
the thiosulfonate moiety as an electrophilic trap, with increased 
specificity for the highly nucleophilic SH-group in the 
development of new cysteine protease inhibitors. We anticipate 
that the thiosulfonate moiety will be a valuable addition to the 
considerable variety of existing SH selective electrophilic traps. 
The presently available electrophilic SH trap containing 
compounds can be roughly divided into three classes: (1) 
irreversible inhibitors such as the tetrafluorophenoxymethyl 
ketones,
10
 aziridine-2,3-dicarboxylates,
11
 epoxyketones, 
epoxyamides, α-alkoxyketones  and diacy-bis-hydrazides;
12
 (2) 
reversible inhibitors such as the nitriles,
13
 nitroalkenes,
14
 
aldehydes
15
 and thiosemicarbazones 
16
 and (3) 1,4-michael 
acceptors such as fumarates,
17
 vinyl α-keto esters, amides and 
acids 
18
 and vinyl sulfones.
19
 
In this work we have drawn inspiration from the simplest 
thiosulfonate, methyl methane thiosulfonate (MMTS,), which 
serves as an SH specific electrophile. MMTS was isolated from 
cauliflower extracts by Nakamura et al in 1996.
20
 After its 
isolation Reddy et al went on to show its chemo-preventive effect 
on colon cancer, demonstrating the link between thiosulfonates in 
diet and therapeutic potential.
21
 MMTS itself is regularly used as 
a reversible thiolating reagent in studies of the natural thiol-
disulfide oxidation state of proteins,
22
 for studying protein S-
nitrosylation
22,23
 and for evaluation of the role of both catalytic 
and structural cysteine residues on enzyme activities.
24–26
 A 
significant next step was the use of functionalized methane 
thiosulfonate derivatives by Matsumoto et al for modifying 
mutants of subtilisin.
27
 
All of these applications exploited the nature of the 
thiosulfonate as an excellent thiophile for highly chemoselective 
targeting of protein thiols. Here, we propose that modification of 
the primed side residue R’ (Fig. 1.) group can be used to control 
reactivity resulting in highly tunable and specific cysteine 
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protease inhibitors. In addition, by modifying the substitution of 
aromatic analogues the electrophilicity of the bivalent sulfur of 
this novel warhead class can be altered. This reactivity profile 
will also be further explored by changing the aromatic ring to the 
aliphatic cyclohexane counterpart for further tuning towards a 
highly chemo-selective warhead. These novel thiosulfonate 
warheads will then be incorporated into suitable cysteine protease 
inhibitors, shown in Fig. 1. 
From the currently available inhibitors we identified K11777, 
a vinyl sulfone based cysteine protease inhibitor, as a starting 
compound for our study as toxicological, ADME and 
pharmacodynamics data has been reported in non-human 
primates.
28
 It is also believed that the vinyl sulfone exhibits a 
high similarity to the thiosulfonate thereby providing an excellent 
reference compound, since the vinyl sulfone is an excellent 
Michael acceptor of thiol-groups alike the thiosulfonate moiety. 
These reactivities can be partly explained by the presence of an 
oxidized sulfur atom in each warhead, which can provide a H-
bond acceptor in the active site of cysteine proteases as is 
illustrated by modelling studies (Fig. 2). Furthermore, by taking 
the K11777 backbone motif and equipping it with our 
thiosulfonate warheads we could access a convenient platform 
for testing of this first inhibitor series to evaluate the effect of 
altering only the warhead moiety. 
This led to very promising inhibitors, which were further 
evaluated in a bioassay to determine their inhibitory effect on 
Schistosoma mansoni, a human blood parasite that expresses 
several cysteine proteases.
29
 
2. Results and discussion 
2.1. Docking study 
Initially, modelling was used as a visual cue to assess the 
potential impact of moving from a vinyl sulfone to a 
thiosulfonate warhead. Papain was selected as a model cysteine 
protease having been widely studied. Docking was very useful to 
visualize the synergistic effect between both the backbone and 
the warhead design for development of specific inhibitors. Thus, 
AutoDock Vina
30
 was utilised for docking studies of ChemDraw 
generated inhibitor constructs with 3D coordinates generated 
through Open Babel software.
31
 Generation of ligand constructs 
and subsequent docking was performed through a Bash script, 
which facilitated a virtual screen directly from ChemDraw (.cdx) 
files, thus named DrawtoDock [see Supporting Information]. 
 
 
 
Fig 2. In situ activation of thiosulfonate warhead (top) and vinyl sulfone 
(bottom) through H bonding to active site residues. H Bonding is highlighted 
with yellow dash. Distance between the active site nucleophile and site of 
attack on the warhead (highlighted by red dash) for the thiosulfonates is 3.2Å 
and for the vinyl sulfone is 3.8Å. 
 
Docking was performed on variants of both the warhead and 
backbone design to identify any site of potential improvement of 
the designed inhibitors. Focusing on the warhead design, one of 
the key findings was that the thiosulfonate warheads may 
undergo activation in the active site of cysteine proteases through 
hydrogen bonding to conserved active site residues (Fig 2.). 
Hydrogen bonding of the thiosulfonate warhead oxygen atoms to 
His-159 may prove particularly important, as this residue forms 
the catalytic dyad with the active site Cys-25. The combination 
of this H-bond donor (His-159) and H-bond acceptor character of 
the thiosulfonate oxygen atoms may in turn polarize the 
thiosulfonate S-S bond, thereby increasing the rate of cleavage. 
Importantly, cysteine proteases utilise the catalytic histidine 
residue as a general acid in their catalytic cycle, facilitating the 
H-bond donor specifically in cysteine proteases as the His-159 is 
in its protonated state. This is in contrast to serine proteases 
which utilise a histidine residue as a general base in their 
catalytic cycle.
32
 As such, these differing catalytic mechanisms 
are favourable for the inhibitory selectivity of thiosulfonates 
towards cysteine proteases. In addition, due to the "soft" 
electrophilic nature, like the disulfide bond, thiosulfonates are 
thiophiles with an increased selectivity towards thiol based 
nucleophiles. It is expected that this intrinsic soft electrophilic 
nature will enhance selectivity towards the cysteine SH of 
cysteine proteases and possibly also toward, for example, protein 
kinases having a cysteine-SH in their active site. Therefore, we 
believe that both of the above characteristics are favourable for 
development of thiosulfonates as a highly selective warhead 
class. 
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Fig 1. Proposed inhibitor design (centre) based on the backbone of 
cysteine protease inhibitor K11777 (top left) deriving a novel warhead 
design inspired by MMTS (bottom left) and controlling the 
electrophilicity by altering the R' substituent on the hexavalent sulfur 
(right). 
  
 
 
 
 
Fig 3.  Comparison of binding modes by docking with papain (PDB code 
1CVZ). K11777 (top, green carbon backbone) and the thiosulfonate 27 
(middle, cyan carbon backbone). Overlayed image (bottom) shows high 
agreement with the largest discrepancy in the S3 region, the N-
methylpiperazine cap is anticipated to be freely rotatable in a solvated 
environment. 
 
Furthermore, modelling suggested that the overall 
thiosulfonate inhibitor binding mode was in agreement with the 
known binding mode of K11777 in similar cysteine proteases.
33
 
This was confirmed by also docking K11777 for comparison 
(Fig. 3), for both K11777 and the thiosulfonate inhibitor 
constructs the aromatic ring of the warhead occupies the S1' 
pocket with the homophenylalanine residue occupying the S1, the 
phenylalanine residue occupies the S2 pocket and the N-methyl 
piperazine cap occupies the S3 pocket. The N-methyl piperazine 
cap displays the greatest variability between the thiosulfonate and 
K11777 models, which was expected as this region is solvent 
facing. The RMS determined with the Pymol align function was 
0.320 Å (overlay of 28 atom pairs specified in the Supporting 
Information) of the docked thiosulfonate and docked K11777. 
The largest discrepancy in docking was observed for the N-
methyl piperazine cap, which was expected, as this moiety is 
freely rotatable within the solvated environment. Most notably, 
the bivalent sulfur was poised in a favourable position to 
facilitate nucleophilic attack by Cys-25-SH (Fig. 2), being 3.2 Å 
from the active site thiolate compared with the 3.7 Å observed 
for the vinyl sulfone reference compound K11777 in this 
modelling study. 
Beyond the warhead design, docking studies also showed the 
likely impact of the backbone on the binding affinity of the 
potential inhibitors. Modifications of side chain containing 
residues had the greatest effect with arginine present in the P1 
position (Fig ) resulting in an increased predicted binding affinity 
determined by AutoDock Vina. This was apparent from a 
favourable electrostatic environment created by the backbone 
carbonyls of Ser-21 and Cys-63, which has been previously 
proposed by Turk et al 
34
 as being significant. With this 
information it would be preferable to vary the P1 position side 
chain by introduction together with the thiosulfonate warhead. 
Thus, from these modelling studies it became evident that a 
flexible warhead synthesis is required, which allows for the 
introduction of different (functionalised) amino acid residues at 
the P1 position and here both Arginine and Homophenylalanine 
were further investigated. 
2.2. Thiosulfonate warhead synthesis 
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Scheme 1.  Synthesis of amino acid derived thiosulfonate warheads. 
 
As the warheads were to be incorporated into peptido-mimetic 
sequences, the first challenge was to devise an efficient synthesis 
towards amino acid derived thiosulfonates. This was achieved as 
is outlined in Scheme 1 and applied to both homophenylalanine 
and arginine derivatives. Starting from carboxylic acids 1 and 12, 
amino alcohols 2 and 13, respectively, were obtained by 
esterification followed by reduction. Conversion to mesylates 3 
and 14 allowed introduction of a thioacetate moiety leading to 4 
and 15. These thioacetates could then be easily diversified 
towards either aromatic or aliphatic thiosulfonates. The aromatic 
thiosulfonates 6-9 and 17-20 were prepared by first hydrolysing 
the thioacetates to thiols followed by oxidation with DMSO/air to 
the corresponding disulfides 5 and 16. Further iodine mediated 
oxidative cleavage by a sulfinate salt to the thiosulfonates, 
according to Fujiki et al,
35
 yielded the aromatic thiosulfonates 6-9 
and 17-20 in good to excellent yields. In our hands, the method 
Fig 4. Docking with arginine derived thiosulfonates, H-bonding  
coordination between arginine side chain and bottom of P1 binding pocket 
through the backbone carbonyls of Cys-63 and Ser-21. 
  
of Fujiki et al was not suitable for the preparation of aliphatic 
thiosulfonates. Therefore, In order to obtain the cyclohexane thiol 
derived thiosulfonates, thioacetates 4 and 15 were hydrolysed 
under an inert atmosphere to obtain the corresponding thiols, 
which were then directly reacted with cyclohexane sulfonyl 
bromide yielding warhead containing amino acid derivatives 11 
and 22 in excellent yields. The required sulfonyl bromide was 
readily accessible from the corresponding thiol by adapting the 
method of Nishiguchi et al. for obtaining sulfonyl chlorides by 
oxidative chlorination with NCS / HCl in MeCN using NBS/HBr 
instead.
36
 [see Supporting Information] 
 
 
Scheme 2.  Thiosulfonate formation from sulfonyl halides. When X = Cl k2 > 
k1 hence no thiosulfonate, only disulfide is isolated. When X = Br, k1 >> k2 
and thiosulfonate is isolated with no detectable disulfide. 
 
The less reactive corresponding sulfonyl chlorides were 
explored earlier for the synthesis of aliphatic thiosulfonates.  
However, in this case only the symmetrical disulfide 5 or 16 was 
obtained. Hence, it was rationalised that formation of the desired 
thiosulfonate was competing with its decomposition by the thiol 
starting material leading to disulfide 5 or 16 (Scheme 2.). It was 
reasoned that the use of the more reactive sulfonyl bromide 
would lead to a complete consumption of the thiol starting 
material, before it could decompose the obtained thiosulfonate. 
Thus, when using a sulfonylbromide: k1>>k2 and the 
thiosulfonate is preferentially formed whereas when using a 
sulfonylchloride: k2>k1 leading to formation of the disulfide 
(Scheme 2.). 
 
Scheme 3. Thiosulfonate synthesis from alkyl bromide and sodium 
thiosulfonate salts. 
 
Other early attempts towards synthesis of the thiosulfonate 
moiety involved generation of the thiosulfonates directly from 
alkyl bromides via substitution by thiosulfonate salts. This 
reaction was inefficient and low yielding due to a subsequent 
nucleophilic attack of the thiosulfonate salt on the obtained 
thiosulfonate warhead, leading to poor yields due to formation of 
a product (observed by LC-MS: M+32, having a very similar 
1
H-
NMR as the thiosulfonate) proposed to contain an additional 
sulfur atom. (Scheme 3.). 
 
2.3. Coupling thiosulfonate warheads to backbone 
  
 
Scheme 4.  Generating the backbone and coupling the thiosulfonate warhead 
fragments under standard peptide coupling conditions. 
 
The core backbone depicted in Scheme 4. consisting of 
phenylalanine with an N-methyl piperazine urea cap at the N 
terminus, was efficiently constructed by isocyanate formation 
with triphosgene followed by a nucleophilic reaction with N-
methyl piperazine yielding urea 25. Next, the benzyl ester was 
removed by hydrogenolysis to yield carboxylic acid 26 in 
accordance with the literature.
37
 Then, the amino acid derived 
thiosulfonates 6-9, 11, 17-20 and 22 were deprotected with either 
TFA (arginine derivatives) or HCl (homophenylalanine 
derivatives) and coupled to the core backbone moiety 26 by 
standard peptide coupling techniques (Scheme 4.). The 
possibility of using standard peptide coupling reactions was 
desirable and highlighted the suitability of the thiosulfonate 
warheads for incorporation into abundantly present 
peptidomimetic based protease inhibitors. The thiosulfonates 
were stable to both BOP and HCTU coupling conditions so that 
in principle large and diverse peptide based libraries containing 
the thiosulfonate are accessible.  
 
  
2.4. pH stability testing of thiosulfonate warheads 
Obviously, of any newly developed electrophilic trap or warhead, 
first the aqueous stability profile has to be explored. This was 
carried out at pH 6,7 and 8 to represent a reasonable 
physiological pH range. The aqueous stability profiles proved a 
valuable means for quantifying the effect of substitution of the 
aromatic ring on the reactivity of the warheads. (Fig. 5) Not 
surprisingly, it was found that electron withdrawing substituents 
(p-NO2) greatly increased, and electron donating substituents (p-
OMe) decreased the reactivity of the warheads relative to each 
other. The p-NO2 substituted warheads were effectively unstable 
at pH 7 and 8 being degraded completely in less than one hour, 
with a slightly improved half life of ca. 1 hr 45 min at pH 6. The 
p-OMe substituted warheads on the other hand were virtually 
stable at pH 6 and displayed very reasonable half lives of ca. 24 
hrs and 1 hr at pH 7 and 8 respectively. Not entirely 
unexpectedly the aqueous stability was greatly increased when 
moving to the aliphatic (cyclohexane) based warheads, which 
were effectively stable at pH 6 and 7 with a greatly increased half 
life of ca. 6 hrs at pH 8. Having shown the highly tunable nature 
of the thiosulfonates, it was concluded that the aromatic 
analogues were more susceptible to pH dependent hydrolysis and 
that this could be well controlled by the nature of the substituent 
on the aromatic ring. However by moving towards the aliphatic 
counterpart the hydrolytic stability of thiosulfonates can be 
further improved. 
 
2.5. Papain IC50 determination 
Papain was used as the prototype cysteine protease to evaluate 
the novel thiosulfonate warhead containing peptide mimics. The 
well-known cysteine protease inhibitor K11777 (previously 
known as K777) was used as a reference compound.
38
 IC50-
values of all inhibitors are tabulated together with the inhibitory 
curves (Fig. 6). Gratifyingly, all tested thiosulfonates inhibited in 
the submicromolar range. Moreover, the inhibition was of the 
same order of magnitude as that observed for K11777. 
Determination of the IC50 values also showed that increasingly 
reactive thiosulfonate warheads (based both on the predicted 
reactivity and the observed aqueous stability) were less potent. 
This effect may be due to partial decomposition of the more 
reactive analogues. It is reasonable to suggest that moving 
forward to more complex biological systems the effects of 
stability as such will become less important and the role of other 
potential nucleophiles, such as circulating thiols, will be more 
significant. Hence, this information is being used to develop a 
new, less reactive but more potent inhibitor series. A particularly 
important finding was that when moving from the aromatic to the 
aliphatic warheads a significant increase was found in terms of 
stability (see aqueous stability profiles, Fig. 5) with no 
significant loss in potency (compound 36, 168 nM) or a slight 
improvement in potency (compound 35, 106 nM) when 
compared with their aromatic counterparts. This suggested that 
the cyclohexane ring is well tolerated in the S1' position of 
Figure 5. Aqueous stability testing of homophenylalanine derived compounds 30 (left) 29 (centre) and 36 (right). Results were obtained by HPLC 
quantification in 0.1M phosphate buffer at the described pH and peaks integrated against Ac-Phe-OH as an internal standard. 
Figure 6. IC50 determination of inhibitors against papain. IC50 curves (left) are shown for both homophenylalanine (top) and arginine (bottom) derived 
warheads. Assay pH: pH 6.5 (0.1M Phosphate buffer). Assay time: 1 hr incubation time. Curves have been staggered to prevent overlapping for 
visualization. Tabulated IC50 values (right) shown. IC50 of K11777 was also determined as a reference compound. 
  
papain. When comparing this with the IC50 value of K11777 at 
81 nM this was a very encouraging result, highlighting that the 
thiosulfonate containing inhibitors are able to perform as well as 
current cysteine protease inhibitors (within the same order of 
magnitude). With these results in hand we moved forward to 
testing on schistosomula, the larval stage of S. mansoni in 
humans. 
2.6. Inhibitory activity against a human blood fluke  
 
S. mansoni is a trematode blood fluke causing acute and 
chronic intestinal schistosomiasis (bilharzia) in humans. 
Schistosomiasis is widely prevalent in Africa, Middle East, and 
South America affecting more than 200 million people. Large-
scale elimination activities are ongoing and praziquantel, the only 
schistosomiasis medication, is widely deployed by mass drug 
administration programs. New antischistosomal drug candidates 
are urgently needed since reduced susceptibility to praziquantel 
has been ongoing for many decades.
39,40
 Research on candidate 
antischistosomal targets has focused on digestive enzymes in S. 
mansoni since the parasite feeds on the haemoglobin of red blood 
cells, essential for the parasite’s growth, development, and 
reproduction.
41
 Papain like cysteine proteases play a major role in 
haemoglobin degradation and have become an important drug 
target.
42–44
 Namely, the cathepsin B like cysteine protease 
SmCB1 for which K11777, the reference compound in this study, 
showed high efficacy against the S. mansoni parasite in the 
murine model.
45
 Furthermore K11777 has been utilised to probe 
the structural basis for inhibition of SmCB1, providing a 
foundation for the thiosulfonates derivatives presented.
33
 This 
study evaluated the drug activity of 10 thiosulfonate derivatives 
against the larval stage of S. mansoni in vitro with half of the 
compounds showing high activity.  
Thiosulfonate derivates 27 - 36 and K11777 were tested for 
inhibition of S. mansoni viability. For the in vitro drug 
susceptibility assay, schistosomula - the Schistosoma larval stage 
that occurs shortly after human skin penetration – were incubated 
with the compounds at various concentrations and worm viability 
was determined by morphology and motility assessment. K11777 
is a known experimental cysteine protease inhibitor of S. mansoni 
and was included as an active control drug in all assays.
45
 Further 
active assay controls included mefloquine (MQ) and auranofin 
(AU), respectively.
46
 Viability of schistosomula during the 
culture duration was controlled for ‘medium only’ and for 1% 
DMSO (drug solvent), respectively.  
All derivatives were first screened at 30 µM and 
schistosomula viability was assessed 1 day, 3 days and 7 days 
after assay start. Amongst the 10 compounds tested, 27, 28, 29, 
30, and 36 were highly active at 7 days of drug exposure (Fig. 7). 
That compounds 31 - 35 having the arginine side chain in the P1 
position were devoid of any activity in the parasite, may have 
looked surprising at a first glance, since they were even slightly 
more active in the papain assay than the homophenylalanine side 
chain containing compounds 27 - 30 and 36. However, alike 
K11777, the hydrophobic homophenylalanine side chain in 27 -
30 and 36 may have allowed for a better penetration of the 
parasite and subsequent biocidal activity. Active compounds 
were further tested at a serial, 3-fold diluted concentration range 
to determine the IC50 in schistosomula at 3 days and 7 days drug 
exposure (Table 1). The dose-response (Fig. 8) followed an 
approximate sigmoidal response for all derivatives at 7 days drug 
exposure. All control compounds (MQ, AU and K11777) were 
highly active at 3 days and 7 days drug exposure with IC50’s well 
below 10 µM (Table 1). IC50 values of the thiosulfonate derivates 
27, 28, 29, 30, and 36 against larval stage schistosomula ranged 
between 10 µM and 30 µM and are promising compounds. 
Compounds 29, 30 and 36 were the most active of the derivatives 
with IC50's of about 13.5 µM, while the standard, K11777, had an 
IC50 of 7.3 µM after 7 days showing higher activity against larval 
S. mansoni parasites. Potency again correlated with stability, 
especially evident with the most stable and potent compounds 29 
and 36, as seen in the earlier papain assay (section 2.5). 
Observing that the least stable inhibitor 30 displays comparable 
potency to the most stable 36 may be a result of off target effects 
by decomposition products, as rapid decomposition of inhibitor 
30 is expected in this assay (pH 7.3) based on earlier observed 
stability data (Fig. 5). The increased activity of 36 as compared 
to 27 -30, may reflect the increased stability of the cyclohexane 
ring containing thiosulfonate warhead (Fig. 5). Thus, these new 
warhead containing compounds are promising starting 
compounds that deserve further development and investigation as 
promising potential anti parasitic compounds. 
Table 1. Mean IC50 (SD) of compounds assessed in schistosomula in vitro 
drug susceptibility assays. Compounds were tested at the indicated 
concentration range and IC50-values were determined for 3 days and 7 days of 
drug exposure. Assays were done 3 times with triplicate measurements. MQ 
(mefloquine), AU (auranofin). 
Figure 7. In vitro drug susceptibility screen of schistosomula. Mean % 
viability of schistosomula after drug exposure for 1 day, 3 days and 7 days. 
Derivatives (27 - 36) and K11777 control were tested at 30 µM, MQ 
(mefloquine) at 100 µM, and AU (auranofin) at 1 µM. ND (no drug, medium 
only) and DMSO control for schistosomula viability. Assay was done in 
triplicate.  
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3. Conclusions 
An efficient synthesis towards amino acid derived 
thiosulfonates has been developed and applied to molecular 
construction of peptidomimetic cysteine protease inhibitors. This 
synthesis allowed for a late stage introduction of the electrophilic 
trap. It is envisioned that this late stage functionalisation by a 
wide range of warheads, each with differing reactivity profiles, 
will prove to be an invaluable feature in future syntheses of 
warhead containing inhibitors. Mechanistically, the 
thiosulfonates offer a soft electrophilic centre, which will 
inherently be more selective for sulfur nucleophiles. In 
combination with the in situ activation, observed in modeling 
studies through hydrogen bonding to highly conserved catalytic 
residues, the thiosulfonates may represent a valuable new class of 
cysteine protease selective electrophilic traps. Furthermore, a 
synergistic effect upon binding has been observed in modeling 
studies of both warhead and the backbone. This led to improved 
inhibitor potency by tuning of the warhead reactivity as well as 
attempts to optimize binding interactions of the backbone in our 
test system. The modelling studies predicted potential in situ 
activation of the novel thiosulfonate warhead and identified 
improvements to the initial inhibitor binding by varying the side 
chain utilised, which correlated well with subsequent IC50 values. 
This was combined with aqueous stability profiles, which also 
correlated with improved IC50 values thereby supporting the 
design of future thiosulfonate warheads containing inhibitors. 
Modelling successfully predicted the most potent residues, 
aqueous stability showed the most stable warheads and the 
correlation between both was reflected in the IC50 values leading 
to the most potent inhibitor 35. Most notably the large increase in 
stability of the aliphatic analogues was not detrimental to potency 
but even met with an improvement. Next, the thiosulfonate 
derived inhibitors have been found to be effective on S. mansoni, 
a human blood parasite, with 36 displaying the highest potency. 
Although in this case the predicted most potent inhibitors 
carrying an arginine residue in the P1 position (based on 
modeling and the papain test system) were found to be less 
active, this is believed to be a permeability issue. Thus, the 
described inhibitor series can already compete with the known 
vinyl sulfone based cysteine protease inhibitor K11777 and 
efforts are underway to further down regulate the thiosulfonate 
warhead reactivity, which should yield more potent and selective 
warheads. The robust synthesis towards aliphatic thiosulfonates 
outlined in scheme 1 was the result of several optimizations and 
should facilitate further diversification of future inhibitors by 
changing the used sulfonyl bromide. This, together with the 
possibility of incorporating suitable substituents occupying both 
P1, P2,... and P1', P2',... positions is highly promising for obtaining 
cysteine protease inhibitors with increased specificity.  
4. Experimental 
4.1. Chemistry 
4 .1 .1 .  Materials  and methods   
Reagents: All reagents and starting materials (were applicable) 
were obtained from either Sigma Aldrich
®
 or Fluorochem Ltd. of 
the highest available quality, and utilised without further 
purification.  
Solvents: All solvents were obtained from Fisher Scientific. 
Where necessary (under strict anhydrous conditions) solvents 
were obtained from a dry source. All deuterated solvents for 
NMR were obtained from Cambridge Isotope Laboratories, Inc.  
Reactions: Air and moisture sensitive reactions were performed 
under a nitrogen atmosphere. All glassware used was dried under 
reduced pressure with heating (250
o
C) from a heat gun. All 
reactions were conducted in septa sealed vessels with equipped 
with a nitrogen balloon, unless otherwise stated, and stirred with 
the use of a magnetic stirrer bead. A glass stopper replaced the 
rubber septum in strongly acidic reaction conditions, such as Boc 
removal with TFA.  
Thin Layer Chromatography (TLC) All TLC’s were conducted 
on aluminium backed TLC plates coated (0.25 mm), with silica 
gel 60 F254 obtained from Merck. Compounds were then detected 
by fluorescent quenching at 254 nm, by UV light from a UV 
Minerallight
®
 lamp. Non-fluorescent quenching substances were 
visualised by oxidative staining with KMnO4 (2.00 g in 400 mL 
water), or Ninhydrin (1.5 g in 100 mL n-Butanol, 3 mL AcOH) 
for staining amines. Stained TLC plates were developed by 
Figure 8. Dose-response curves. Viability (%) is displayed per compound concentration (log10, µM). Drug exposure: blue: 1 day, red: 7days. Dots and 
triangles represent individual data points per drug concentration (triplicates) from one exemplary assay. Lines represent the modelled curve fit. MQ 
(mefloquine), AU (auranofin).  
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heating with a heat gun (250
o
C), on a hot plate (250
o
C) or a 
combination of both as required.  
Automated column chromatography: was conducted with the 
Biotage
®
 Isolera One
®
 automated chromatograph. Products were 
purified on Biotage
®
 SNAP Ultra cartridges pre packed with 
Biotage
®
 HP-sphere
™
 Spherical silica. UV absorption was 
detected with Biotage
®
 Isolera
™
 Spektra UV detector at both 
UV1 (254 nm) and UV2 (280 nm) to identify fractions for 
collection in combination with TLC analysis.  
Preparative HPLC: was conducted with the Agilent 
Technologies 1260 Infinity Preparative-scale Purification system. 
Separation was achieved on a Phenomenex Gemini
®
, 1    C   
     A AXIA, 250 x 21.2 mm. A linear gradient of 5 → 95% 
MeCN in Ultra pure water with 0.1% TFA was utilised. All runs 
were conducted over 80 minutes with a flow rate of 12.5 
mL/Min. Fraction collection was based on UV absorption 
detected at both 214 and 254 nm.  
LC-MS: was conducted with a Thermo Scientific, Dionex 
UltiMate 3000 standard LC system coupled to a Thermo 
Scientific LCQ Fleet™ Ion trap mass spectrometer. Separations 
were achieved with a Dr. Maisch GmbH Reprosil Gold 120 C18, 
3  m,  5  x 4 mm column with a flow rate of 1 mL/Min. A linear 
gradient of 5 → 95% MeCN in Ultra pure water with  . % TFA 
over either 40 min. or 10 min. was utilised and retention times 
given. UV absorption was detected at 214 nm.  
Nuclear Magnetic Resonance (NMR): characterization employed 
a Bruker
®
 400 MHz spectrometer measuring 
1
H, 
13
C, COSY and 
HSQC as required. Chemical shifts are given in parts per million 
(ppm). Shifts were downfield of a TMS reference (δTMS = 
0 ppm) and the resonances of the rest protons of the deuterated 
solvents served as internal standard.
47
 CDCl3: 7.26 ppm (
1
H-
NMR), 77.16 ppm (
13
C-NMR); Methanol-d4: 3.31 ppm (
1
H-
NMR), 49.0 ppm (
13
C-NMR). 
1
H-
1
H COSY experiments and 
1
H-
13
C HSQC experiments were also conducted for correct signal 
assignment as required.  
4.1.2.  General  procedures   
(1) General procedure for amino acid derived methyl esters: the 
Boc protected amino acid (1.00 equiv.) and K2CO3 (3.00 equiv.) 
were slurried in DMF (3.5 mL/mmol) for 1.5 hrs. under a 
nitrogen atmosphere. Methyl Iodide (3.00 equiv.) was added 
dropwise and the solution stirred overnight. TLC (0.1% AcOH in 
a suitable mixture of EtOAc and Pet-ether 40-60) confirmed 
reaction completion and the solution was evaporated to dryness. 
The residue was taken up in EtOAc (10 mL/mmol), washed with 
water (10 mL/mmol), aqueous back extracted with EtOAc 
(3 × 10 mL/mmol). The combined organic layers were washed 
with 5% aq. Na2SO3 (3× 20 mL/mmol), brine (50 mL/mmol) and 
dried over MgSO4. Concentration in vacuo yielded the title 
compound with no further purification required unless otherwise 
stated.  
(2) General procedure for obtaining amino alcohols by methyl 
ester reduction: The previously formed methyl ester (1.00 equiv.) 
and LiCl (2.50 equiv.) were stirred in dry THF (3.00 mL/mmol) 
and cooled to 0
o
C for 15 min. under a nitrogen atmosphere. 
NaBH4 (2.50 equiv.) was added and stirred for 15 min. followed 
by the addition of EtOH (4 mL/mmol). The solution was stirred 
for 1 hr. at 0
o
C before removal of the ice bath. TLC (suitable 
eluent mixture of EtOAc and pet-ether 40-60) confirmed reaction 
completion after 3 hrs. Water (1.5 mL/mmol) was added 
followed by addition of sat. NH4Cl (2.5 mL/mmol) and EtOAc 
(10 mL/mmol). The aqueous and organic layers were separated 
and the aqueous layer was back extracted with EtOAc 
(3 × 10 mL/mmol). The combined organic layers were washed 
with brine (50 mL/mmol) and dried over MgSO4. Concentration 
in vacuo yielded the title compound without further purification 
unless otherwise stated.  
(3) General procedure for preparation of mesylates: The 
previously formed alcohol (1.00 equiv.) was dissolved in DCM 
(10 mL/mmol) and cooled to 0
o
C. Triethylamine (5.00 equiv.) 
was added followed by MsCl (3.50 equiv.) and stirred overnight. 
Completion of the reaction was confirmed by TLC (suitable 
concentration of EtOAc, pet-ether) and the solution washed with 
1M KHSO4 (2 × 5 mL/mmol), water (2 × 15 mL/mmol), brine 
(30 mL/mmol) and dried over MgSO4. Concentration in vacuo 
yielded the title compound with no further purification required 
unless otherwise stated.  
(4) General procedure for preparation of thioacetates by 
mesylate substitution: CsCO3 (1.00 equiv.) was suspended in 
DMF (10mL/mmol) and thioacetic acid (2.00 equiv.) was added 
under an N2 atmosphere before stirring for 15 min. In a separate 
flask the previously formed mesylate (1.00 equiv.) was dissolved 
in DMF (2 mL/mmol) and added dropwise to the CsCO3/HSAc 
solution before DMF (2 mL/mmol) was used to rinse any 
remaining mesylate into the CsCO3/HSAc solution. The reaction 
vessel was then covered with aluminium foil and stirred 
overnight, TLC confirmed completion (suitable mixture of 
EtOAc and pet-ether 40-60). The reaction mixture was 
evaporated to dryness and taken up in EtOAc (10 mL/mmol), 
washed with water (3 × 5 mL/mmol), back extracted with EtOAc 
(4 × 5 mL/mmol). The combined organic layers were washed 
with brine (7.5 mL/mmol) and dried over MgSO4. Purification by 
column chromatography (using a suitable gradient of EtOAc and 
pet-ether 40-60) yielded the title compound. 
(5) General Procedure for the preparation of a disulfide from a 
thioacetate: The previously prepared thioacetate (1.00 equiv.) 
was dissolved in EtOH (25 mL/mmol) and KOH (3.00 equiv.) 
was added followed by DMSO (1% by volume) and water (2% 
by volume). Air was bubbled through the solution for 30 min. 
before stirring vigorously in an open topped flask overnight. TLC 
(suitable eluent mixture of EtOAc, pet-ether 40-60) confirmed 
reaction completion. The thiol formation was always observed as 
a spot on TLC with a higher Rf value than the disulfide, which 
tends to have an Rf value close to that of the starting material 
thioacetate. The solution was then evaporated to dryness, taken 
up in EtOAc (20 mL/mmol), washed with water 
(3 × 20 mL/mmol), brine (20 mL/mmol), dried over MgSO4 and 
concentrated in vacuo to yield the title compound which was 
used without further purification unless otherwise stated.  
(6) General procedure for preparation of a thiol from a 
thioacetate: All solvents used in this procedure were first 
degassed by bubbling N2 gas through for 30 min. Under a N2 
atmosphere the previously prepared thioacetate (1.00 equiv.) was 
dissolved in EtOH (25 mL/mmol) and KOH (3.00 equiv.) was 
added and stirred overnight. TLC (suitable eluent mixture of 
EtOAc, pet-ether 40-60) confirmed reaction completion. The 
solution was then evaporated to dryness on a rotary evaporator 
fitted with a N2 balloon to ensure a N2 atmosphere was 
maintained upon removal from the rotary evaporator. The 
resultant residue was taken up in EtOAc (20 mL/mmol), washed 
with water (3 × 20 mL/mmol), brine (20 mL/mmol), dried over 
MgSO4 and concentrated in vacuo to yield the title compound 
which was used without further purification. 
(7) General procedure for thiosulfonate formation from the 
disulfide: The previously formed disulfide (1.00 equiv.) was 
dissolved in DCM (10 mL/mmol) and the respective sodium 
sulfinate salt (3.20 equiv.) was added followed by iodine 
  
(2.00 equiv.). Completion was confirmed by TLC (relevant 
concentration of EtOAc, pet-ether) after 1.5 hrs. The reaction 
mixture was diluted with DCM (10 mL/mmol), washed with 1M 
Na2SO3 (2 × 10 mL/mmol), water (20 mL/mmol), back extract 
aqueous with DCM (10 mL/mmol), combine organic and wash 
with brine (10 mL/mmol) and dry over MgSO4. Purification by 
column chromatography (relevant gradient of EtOAc, pet-ether) 
yielded the title the title compound.  
(8) Thiosulfonate formation from Sulfonyl bromide: Cyclohexane 
sulfonyl bromide which was prepared by modification of the 
procedure of Nishiguchi et al.
36
 (see Supporting Information) 
(1.2 equiv.) was stirred in DCM (10 mL/mmol) and DiPEA was 
added (1.2 equiv.). The solution was cooled to 0
o
C in an ice bath 
and the relevant thiol dissolved in DCM (10 mL/mmol) was 
added dropwise. Reaction completion was confirmed by TLC 
after 30 min., the solution was diluted with 10 mL/mmol DMF 
and evaporated to dryness before being taken up in EtOAc 
(10 mL/mmol) and washed with (3 × 10 mL/mmol) 1M KHSO4, 
Brine (1 × 10 mL/mmol), dried over MgSO4 and concentrated in 
vacuo to yield the title compound.  
(9) Peptide coupling of the warhead containing derivative to 
backbone peptides - Method 1: The free amine hydrochloride salt 
was prepared from the relevant Boc protected amine by stirring 
in 2M HCl/dioxane (10 mL/mmol) for 1 hr. and completion 
confirmed by TLC (15% EtOAc, n-Hexane). The solution was 
then evaporated to dryness and co-evaporated with toluene 
(2 × 10 mL/mmol) yielding the unprotected amine as the 
hydrochloride salt. The amine was then taken up in DCM 
(10 mL/mmol) and BOP (1.20 equiv.) was added followed by 
DiPEA (initially 2.00 equiv. with more added as necessary to 
maintain basic conditions) and reaction progress followed by 
TLC (10% MeOH in DCM). Coupling was usually complete 
within 3 hrs. at which point the solution was diluted with EtOAc 
(100 mL/mmol), washed with water (2 × 50 mL/mmol), brine 
(2 × 50 mL/mmol), dried over MgSO4 and purified by column 
chromatography (0 → 10% MeOH, DCM) yielding the title 
compounds. Purification by preparative HPLC (5 → 95% MeCN, 
water, 0.1% TFA) yielded the title compounds as fluffy white 
TFA salts after lyophilisation.  
(10) Peptide coupling of the warhead containing derivative to 
backbone peptides - Method 2: The free amine TFA-salt was 
prepared from the relevant Boc-Arg(Pbf)-warhead by stirring in 
TFA (10 mL/mmol) with 2% water and 1% TIPS for 2 hr. and 
completion confirmed by LCMS to ensure both Boc and Pbf 
removal. The solution was then evaporated to dryness and co-
evaporated with toluene (2 × 10 mL/mmol) yielding the 
unprotected amine as the bis-TFA salt. The amine was then taken 
up in DCM (10 mL/mmol) and HCTU (1.20 equiv.) was added 
followed by DiPEA (initially 2.00 equiv. with more added as 
necessary to maintain basic conditions) and reaction progress 
followed by TLC (10% MeOH, DCM). Coupling was usually 
complete within 3 hrs. at which point the solution was diluted 
with DMF (10mL/mmol) and evaporated to dryness. The residue 
was taken up in 0.1% TFA in water and freeze dried before 
purification by reverse phase column chromatography (5 → 4 % 
MeCN, water, 0.1% TFA) yielding the title compounds. Further 
purification by preparative HPLC yielded compounds as fluffy 
white TFA salts after lyophilisation.  
4.1.3.  Compound synthes is  
Boc-HomoPhe-Ψ[CH2OH] (2): step 1, methyl ester was 
prepared according to general procedure 1 on a 1 mmol (279 mg) 
scale. Yield: 280 mg, 0.955 mmol, 96%. 
1
H NMR (400 MHz, 
CDCl3) δ 7.24 – 7.09 (m, 5H), 5.00 (d, J = 8.4 Hz, 1H), 4.29 (dd, 
J = 12.5, 7.5 Hz, 1H), 3.64 (s, 3H), 2.65 – 2.55 (m, 2H), 2.14 – 
2.03 (m, 1H), 1.93 – 1.82 (m, 1H), 1.38 (s, 9H). 
13
C NMR (101 
MHz, CDCl3) δ  73. 6,  55.35,  4 .77,  2 .4 ,  2 .4 ,  26. 5, 
79.94, 53.25, 52.27, 34.40, 31.64, 28.33. LC-MS (Linear gradient 
5 → 95% MeCN,  . % TFA,    min): Rt (min): 6.91 (ESI-MS 
(m/z): 293.66 (M
+
)).  
Step 2, reduction to the alcohol was achieved according to 
general procedure 2 on a 0.933 mmol (272 mg) scale. Yield: 
239 mg, 0.901 mmol, 97%. 
1
H NMR (400 MHz, CDCl3) δ 7.23 – 
7.07 (m, 5H), 4.73 (d, J = 8.0 Hz, 1H), 3.57 (d, J = 10.2 Hz, 2H), 
3.48 (br s, 1H), 2.75 (s, 1H), 2.68 – 2.53 (m, 2H), 1.82 – 1.72 (m, 
1H), 1.72 – 1.60 (m, 1H), 1.38 (s, 9H).
13
C NMR (101 MHz, 
CDCl3) δ  56.47,  4 .55,  2 .45,  2 .36,  25.9 , 79.65, 65.7 , 
52.49, 33.32, 32.40, 28.42. LC-MS (Linear gradient 5 → 95% 
MeCN, 0.1% TFA, 10 min): Rt (min): 6.21 (ESI-MS (m/z): 
265.75 (M
+
)). HRMS: calcd. for C15H23NO3Na, 288.1570 
[M+Na
+
]; found 288.1559. 
Boc-HomoPhe-Ψ[CH2OMs] (3): Prepared according to 
general procedure 3 on a 1 mmol (263 mg) scale. Yield: 335 mg, 
0.976 mmol, 98%. 
1
H NMR (400 MHz, CDCl3) δ 7.35 – 7.18 (m, 
5H), 4.66 (d, J = 8.7 Hz, 1H), 4.29 (dd, J = 9.9, 4.0 Hz, 1H), 4.23 
(dd, J = 10.1, 4.1 Hz, 1H), 3.90 (br s, 1H), 3.03 (s, 3H), 2.83 – 
2.64 (m, 2H), 1.99 – 1.81 (m, 2H), 1.48 (s, 9H). 
13
C NMR (101 
MHz, CDCl3) δ  55.3 ,  4 .7 ,  2 .57,  2 .37,  26.22, 7 . 4, 
49.42, 37.56, 32.98, 32.09, 28.34. LC-MS (Linear gradient 5 → 
95% MeCN, 0.1% TFA, 10 min): Rt (min): 6.59 (ESI-MS (m/z): 
366.08 (M+Na
+
)).). HRMS: calcd. for C16H25NO5Na, 366.1346 
[M+Na
+
]; found 366.1343. 
Boc-HomoPhe-Ψ[CH2SAc] (4): Prepared according to general 
procedure 4 on a 23.5 mmol (8.07 g) scale. Purified by column 
chromatography   →   % EtOAc, Hexane. Yield: 5.55 g, 
17.2 mmol, 73%. 
1
H NMR (400 MHz, CDCl3) δ 7.24 – 7.08 (m, 
5H), 4.46 (d, J = 9.1 Hz, 1H), 3.73 (br s, 1H), 3.05 (dd, J = 13.9, 
4.8 Hz, 1H), 2.97 (dd, J = 13.9, 7.0 Hz, 1H), 2.69 – 2.53 (m, 2H), 
2.28 (s, 3H), 1.81 – 1.70 (m, 1H), 1.70 – 1.61 (m, 1H), 1.38 (s, 
9H). 
13
C NMR (101 MHz, CDCl3) δ  55.5 ,  4 .52,  2 .5 , 
128.49, 126.11, 79.54, 50.45, 36.33, 34.06, 32.49, 30.72, 28.51. 
LC-MS (Linear gradient 5 → 95% MeCN,  . % TFA, 4  min): 
Rt (min): 22.14 (ESI-MS (m/z): 323.67 (M
+
)). HRMS: calcd. for 
C17H25NO3SNa, 346.1447 [M+Na
+
]; found 346.1437. 
Boc-HomoPhe-Disulfide (5): Prepared according to general 
procedure 5 on a 2.67 mmol (864 mg) scale. Yield: 605 mg, 
1.08 mmol, 81%. 
1
H NMR (500 MHz, CDCl3) δ 7.23 – 7.08 (m, 
10H), 4.90 (br s, 2H), 3.81 (br s, 2H), 2.92 (d, J = 11.9 Hz, 2H), 
2.72 (dd, J = 14.2, 6.3 Hz, 2H), 2.65 (dd, J = 9.8, 5.0 Hz, 2H), 
2.57 (ddd, J = 13.8, 9.8, 6.6 Hz, 2H), 1.86 (br s, 2H), 1.70 (br s, 
2H), 1.39 (s, 18H). 
13
C NMR (101 MHz, CDCl3) δ  55.5 , 
141.46, 128.44, 125.98, 49.96, 45.05, 35.10, 32.44, 28.49. LC-
MS (Linear gradient 5 → 95% MeCN,  . % TFA,    min): Rt 
(min): 8.36 (ESI-MS (m/z): 860.89 (M
+
), 883.20 (M+Na
+
)). 
HRMS: calcd. for C30H44N2O4S2Na, 583.2635 [M+Na
+
]; found 
583.2610. 
Boc-HomoPhe-Ψ[CH2SH] (10): Prepared according to general 
procedure 6 on a 1.20 mmol (684 mg) scale. Yield: Quant. Due 
to air sensitivity the thiol was not characterized and used directly 
in following reaction.  
Boc-HomoPhe-Ψ[CH2SSO2-Ph] (6): Prepared according to 
general procedure 7 on a 0.196 mmol (110 mg) scale. Purified by 
automated column chromatography 5 → 25% EtOAc, pet-ether 
40-60. Yield: 90 mg, 0.213 mmol, 54%. 
1
H NMR (400 MHz, 
CDCl3) δ 7.9  (dd, J =  .3,  .4 Hz, 2H), 7.6  (tt, J = 7.3,  .3 Hz, 
1H), 7.52 (tt, J = 7.5, 1.5 Hz, 2H), 7.29 – 7.23 (m, 2H), 7.18 (tt, J 
= 7.4, 1.3 Hz, 1H), 7.11 (dd, J = 8.3, 1.5 Hz, 2H), 4.67 (d, J = 8.7 
Hz, 1H), 3.86 – 3.74 (m, 1H), 3.22 (dd, J = 13.4, 4.9 Hz, 1H), 
  
3.15 (dd, J = 13.1, 6.3 Hz, 1H), 2.70 – 2.60 (m, 1H), 2.56 (ddd, J 
= 13.9, 9.2, 7.0 Hz, 1H), 1.83 – 1.67 (m, 2H), 1.43 (s, 9H). 
13
C 
NMR (101 MHz, CDCl3) δ  55.24,  44.64,  4 .9 , 133.83, 
129.39, 128.56, 128.37, 127.01, 126.18, 79.79, 49.42, 40.91, 
35.62, 32.26, 28.41. LC-MS (Linear gradient 5 → 95% MeCN, 
0.1% TFA, 40 min): Rt (min): 23.52 (ESI-MS (m/z): 421.57 
(M
+
), 444.07(M+Na
+
)). HRMS: calcd. for C21H27NO4S2Na, 
444.1274 [M+Na
+
]; found 444.1260. 
Boc-HomoPhe-Ψ[CH2SSO2-(p-Me)Ph] (7): Prepared 
according to general procedure 7 on a 0.212 mmol (119 mg)  
scale. Purified by automated column chromatography 5 → 25% 
EtOAc, pet-ether 40-60. Yield: 157 mg, 0.266 mmol, 63%. 
1
H 
NMR (400 MHz, CDCl3) δ 7.7  (d, J =  .4 Hz, 2H), 7.32 – 7.28 
(m, 2H), 7.28 – 7.23 (m, 2H), 7.21 – 7.14 (m, 1H), 7.13 – 7.09 
(m, 2H), 4.71 (d, J = 8.7 Hz, 1H), 3.87 – 3.76 (m, 1H), 3.20 (dd, J 
= 13.1, 4.2 Hz, 1H), 3.14 (dd, J = 13.2, 6.2 Hz, 1H), 2.70 – 2.60 
(m, 1H), 2.56 (ddd, J = 13.9, 9.2, 7.0 Hz, 1H), 2.41 (s, 3H), 1.81 
– 1.68 (m, 2H), 1.43 (s, 9H). 
13
C NMR (101 MHz, CDCl3) δ 
155.25, 144.92, 141.80, 140.95, 129.94, 128.51, 128.35, 127.08, 
126.13, 79.70, 49.41, 40.79, 35.59, 32.25, 28.39, 21.69. LC-MS 
(Linear gradient 5 → 95% MeCN,  . % TFA,    min): Rt (min): 
7.56 (ESI-MS (m/z): 435.65 (M
+
), 458.07(M+Na
+
)). HRMS: 
calcd. for C22H29NO4S2Na, 458.1430 [M+Na
+
]; found 458.1417. 
Boc-HomoPhe-Ψ[SSO2-(p-OMe)Ph] (8): Prepared according 
to general procedure 7 on a 0.212 mmol (119 mg) scale. Purified 
by automated column chromatography 5 → 25% EtOAc, pet-
ether. Yield: 158 mg, 0.350 mmol, 83%. 
1
H NMR (400 MHz, 
CDCl3) δ 7.   – 7.80 (m, 2H), 7.31 – 7.24 (m, 2H), 7.22 – 7.15 
(m, 1H), 7.15 – 7.10 (m, 2H), 7.01 – 6.93 (m, 2H), 4.62 (d, J = 
8.7 Hz, 1H), 3.87 (s, 3H), 3.86 – 3.77 (m, 1H), 3.20 (dd, J = 13.6, 
4.2 Hz, 1H), 3.15 (dd, J = 13.3, 6.0 Hz, 1H), 2.72 – 2.63 (m, 1H), 
2.58 (ddd, J = 13.9, 9.1, 7.1 Hz, 1H), 1.86 – 1.70 (m, 2H), 1.44 
(s, 9H). 
13
C NMR (101 MHz, CDCl3) δ  63.75,  55.25,  40.96, 
136.28, 129.43, 128.52, 128.35, 126.13, 114.43, 79.69, 55.80, 
49.40, 40.75, 35.61, 32.26, 28.39. LC-MS (Linear gradient 5 → 
95% MeCN, 0.1% TFA, 10 min): Rt (min): 7.39 (ESI-MS (m/z): 
451.62 (M
+
), 474.06 (M+Na
+
)). HRMS: calcd. for 
C22H29NO5S2Na, 474.1379 [M+Na
+
]; found 474.1366. 
Boc-HomoPhe-Ψ[CH2SSO2-(p-NO2)Ph] (9): Prepared 
according to general procedure 7 on a 1 mmol (560 mg) scale. 
Purified by automated column chromatography 5 → 25% EtOAc, 
pet-ether. Yield: 520 mg, 1.11mmol, 56%. 
1
H NMR (400 MHz, 
CDCl3) δ  .34 (d, J =  .9 Hz, 2H),  .   (d, J =  .9 Hz, 2H), 7.3  
– 7.23 (m, 2H), 7.22 – 7.16 (m, 1H), 7.14 – 7.08 (m, 2H), 4.52 (d, 
J = 8.4 Hz, 1H), 3.82 – 3.69 (m, 1H), 3.27 (dd, J = 13.6, 5.4 Hz, 
1H), 3.21 (dd, J = 13.9, 6.2 Hz, 1H), 2.68 (ddd, J = 14.6, 9.1, 5.9 
Hz, 1H), 2.59 (ddd, J = 13.9, 9.0, 7.1 Hz, 1H), 1.86 – 1.76 (m, 
1H), 1.76 – 1.66 (m, 1H), 1.43 (s, 9H). 
13
C NMR (101 MHz, 
CDCl3) δ  55.  ,  5 .46,  49.72,  4 .59,  2 .62,  2 .35, 
128.27, 126.34, 124.72, 80.04, 60.47, 49.38, 41.52, 35.54, 32.18, 
28.39, 21.12, 14.28. LC-MS (Linear gradient 5 → 95% MeCN, 
0.1% TFA, 10 min): Rt (min): 7.32 (ESI-MS (m/z): 466.31 
(M
+
)). HRMS: calcd. for C21H26N2O6S2Na, 489.1124 [M+Na
+
]; 
found 489.1119. 
Boc-HomoPhe-Ψ[CH2SSO2-cHex] (11): Prepared according 
to general procedure 8 on a 0.500 mmol (141 mg) scale. Purified 
by column chromatography 3 → 3 % EtOAc, pet-ether 40-60. 
Yield: 214 mg, Quant. 
1
H NMR (400 MHz, CDCl3) δ 7.3  – 7.25 
(m, 2H), 7.22 – 7.15 (m, 3H), 4.68 (d, J = 8.8 Hz, 1H), 3.90 – 
3.82 (m, 1H), 3.39 (dd, J = 13.4, 4.1 Hz, 1H), 3.18 (dd, J = 13.8, 
7.0 Hz, 1H), 3.17 – 3.11 (m, 1H), 2.77 – 2.61 (m, 2H), 2.31 – 
2.22 (m, 2H), 1.95 – 1.87 (m, 2H), 1.87 – 1.76 (m, 2H), 1.75 – 
1.67 (m, 1H), 1.63 – 1.49 (m, 2H), 1.46 (s, 9H), 1.37 – 1.26 (m, 
2H), 1.26 – 1.15 (m, 1H).
13
C NMR (101 MHz, CDCl3) δ  55.36, 
140.96, 128.53, 128.38, 126.14, 71.37, 50.07, 41.17, 35.88, 
32.26, 28.38, 26.36, 26.21, 25.17, 25.11, 25.04. LC-MS (Linear 
gradient 5 → 95% MeCN,  . % TFA,    min): Rt (min): 7.39 
(ESI-MS (m/z): 427.75 (M
+
)). HRMS: calcd. for 
C21H33NO4S2Na, 450.1743 [M+Na
+
]; found 450.1746. 
 
Boc-Arg(Pbf)-Ψ[CH2OH] (13): Step 1, methyl ester was 
synthesized according to general procedure 1 on a 10 mmol 
(5.27 g) scale. Purified by automated column chromatography 20 
→    % EtOAc, pet-ether 40-60.  Yield: 5.02 g, 9.29 mmol, 
93%. 
1
H NMR (400 MHz, CDCl3) δ  . 2 (s,  H), 6.   – 6.04 (m, 
2H), 5.26 (d, J = 8.3 Hz, 1H), 4.35 – 4.19 (m, 1H), 3.73 (s, 3H), 
3.35 – 3.25 (m, 1H), 3.23 – 3.13 (m, 1H), 2.96 (s, 2H), 2.58 (s, 
3H), 2.52 (s, 3H), 2.09 (s, 3H), 1.87 – 1.75 (m, 1H), 1.70 – 1.55 
(m, 3H), 1.46 (s, 6H), 1.42 (s, 9H). 
13
C NMR (101 MHz, CDCl3) 
δ  73. 7,  5 . 3,  56.29,  56.  ,  3 .47,  33. 5,  32.39, 
124.70, 117.59, 86.49, 80.46, 52.81, 52.60, 43.37, 40.85, 30.71, 
28.74, 28.45, 25.30, 19.40, 18.03, 12.61. LC-MS (Linear gradient 
5 → 95% MeCN,  . % TFA,    min): Rt (min): 6.7  (ESI-MS 
(m/z): 541.12 (M+H
+
)).  HRMS: calcd. for C25H40N4O7SNa, 
563.2510 [M+Na
+
]; found 563.2501. 
Step 2, reduction to alcohol was achieved according to general 
procedure 2 on a 9.29 mmol (5.02 g) scale. Yield: 4.72 g, 
9.21 mmol, 99%. 
1
H NMR (400 MHz, CDCl3) δ 6.39 – 6.12 (m, 
3H), 5.16 (d, J = 7.9 Hz, 1H), 3.64 – 3.51 (m, 3H), 3.31 – 3.15 
(m, 3H), 2.95 (s, 2H), 2.56 (s, 3H), 2.50 (s, 3H), 2.09 (s, 3H), 
1.64 – 1.51 (m, 4H), 1.46 (s, 6H), 1.41 (s, 9H). 
13
C NMR (101 
MHz, CDCl3) δ  5 .92,  56.  ,  56.47,  3 .46,  32.  ,  32.37, 
124.77, 117.67, 86.56, 79.74, 65.12, 43.37, 41.20, 29.03, 28.74, 
28.55, 25.75, 19.43, 18.09, 12.62. LC-MS (Linear gradient 5 → 
95% MeCN, 0.1% TFA, 10 min): Rt (min): 6.15 (ESI-MS (m/z): 
513.08 (M+H
+
)). HRMS: calcd. for C24H40N4O6SNa, 535.2561 
[M+Na
+
]; found 535.2543. 
Boc-Arg(Pbf)-Ψ[CH2OMs] (14): Prepared according to 
general procedure 3 on a 9.21 mmol (4.72 g) scale. Purified by 
automated column chromatography 2  →    % EtOAc, pet-
ether 40-60. Yield: 3.42 g, 5.79 mmol, 63%. 
1
H NMR (400 MHz, 
CDCl3) δ 6.2  – 5.98 (m, 3H), 5.03 (d, J = 9.0 Hz, 1H), 4.23 (dd, 
J = 10.2, 4.2 Hz, 1H), 4.16 (dd, J = 10.2, 4.4 Hz, 1H), 3.90 – 3.79 
(m, 1H), 3.32 – 3.15 (m, 2H), 3.04 (s, 3H), 2.96 (s, 2H), 2.57 (s, 
3H), 2.51 (s, 3H), 2.10 (s, 3H), 1.70 – 1.53 (m, 4H), 1.46 (s, 6H), 
1.42 (s, 9H). 
13
C NMR (101 MHz, CDCl3) δ  59. 7,  56. 9, 
155.96, 138.53, 132.48, 124.90, 117.74, 86.65, 79.97, 71.52, 
49.69, 43.29, 40.95, 37.39, 28.71, 28.67, 28.47, 25.50, 19.42, 
18.06, 14.30, 12.59. LC-MS (Linear gradient 5 → 95% MeCN, 
0.1% TFA, 10 min): Rt (min): 6.40 (ESI-MS (m/z): 591.08 
(M+H
+
)). HRMS: calcd. for C25H42N4O8S2Na, 613.2336 
[M+Na
+
]; found 613.2312. 
Boc-Arg(Pbf)-Ψ[CH2SAc] (15): Prepared according to general 
procedure 5 on a 5.79 mmol (3.42 g) scale. Purified by automated 
column chromatography 2  →    % EtOAc, pet-ether 40-60. 
Yield: 2.98 g, 5.23 mmol, 90%. 
1
H NMR (400 MHz, CDCl3) δ 
6.19 – 6.02 (m, 3H), 4.71 (d, J = 9.2 Hz, 1H), 3.78 – 3.64 (m, 
1H), 3.32 – 3.20 (m, 1H), 3.20 – 3.09 (m, 1H), 2.95 (s, 2H), 3.03 
– 2.86 (m, 2H), 2.58 (s, 3H), 2.52 (s, 3H), 2.35 (s, 3H), 2.09 (s, 
3H), 1.63 – 1.53 (m, 2H), 1.53 – 1.46 (m, 2H), 1.46 (s, 6H), 1.41 
(s, 9H). 
13
C NMR (101 MHz, CDCl3) δ  5 .  ,  56.52,  56.2 , 
138.50, 132.44, 124.69, 117.58, 86.47, 80.04, 50.19, 43.39, 
41.12, 34.15, 32.44, 30.72, 28.75, 28.52, 25.60, 19.41, 18.04, 
12.63. LC-MS (Linear gradient 5 → 95% MeCN,  . % TFA,    
min): Rt (min): 6.74 (ESI-MS (m/z): 571.08 (M+H
+
)). HRMS: 
calcd. for C26H42N4O6S2Na, 593.2438 [M+Na
+
]; found 593.2408. 
  
Boc-Arg(Pbf)-Disulfide (16): Prepared according to general 
procedure 5 on a 4.21 mmol (2.40 g) scale. Purified by automated 
column chromatography 2  →    % EtOAc, pet-ether 40-60.  
Yield: 1.62 g, 1.54 mmol, 73%. 
1
H NMR (400 MHz, CDCl3) δ 
6.47 – 6.18 (m, 6H), 3.91 – 3.77 (m, 2H), 3.40 – 3.13 (m, 4H), 
2.96 (s, 4H), 3.04 – 2.81 (m, 4H), 2.57 (s, 6H), 2.51 (s, 6H), 2.10 
(s, 6H), 1.76 – 1.50 (m, 8H), 1.46 (s, 12H), 1.41 (s, 18H). 
13
C 
NMR (101 MHz, CDCl3) δ  5 .9 ,  56.76,  56.69,  3 .45, 
132.98, 132.42, 124.74, 117.65, 86.52, 79.65, 50.68, 43.42, 
41.01, 31.53, 28.76, 28.64, 26.04, 19.49, 18.11, 12.65. LC-MS 
(Linear gradient 5 → 95% MeCN,  . % TFA,    min): Rt (min): 
7.62 (ESI-MS (m/z): 1055.25 (M+H
+
)). HRMS: calcd. for 
C48H78N8O10S4Na, 1077.4616 [M+Na
+
]; found 1077.4598. 
Boc-Arg(Pbf)-Ψ[CH2SH] (21): Prepared according to general 
procedure 7 on a 3.285mmol scale. Yield: 94%. Thiol was used 
directly in following reaction due to air sensitivity.  
Boc-Arg(Pbf)-Ψ[CH2SSO2-Ph] (17): Prepared according to 
general procedure 7 0.331 mmol (349 mg) scale. Purified by 
automated column chromatography 2  →  0% EtOAc, pet-ether 
40-60. Yield: 142 mg, 0.212 mmol, 32%. 
1
H NMR (400 MHz, 
CDCl3) δ 7.94 – 7.89 (m, 2H), 7.65 – 7.59 (m, 1H), 7.58 – 7.51 
(m, 2H), 6.30 – 6.02 (m, 3H), 5.01 (d, J = 8.8 Hz, 1H), 3.86 – 
3.66 (m, 1H), 3.23 – 3.10 (m, 3H), 3.06 (dd, J = 13.7, 6.8 Hz, 
1H), 2.95 (s, 2H), 2.56 (s, 3H), 2.50 (s, 3H), 2.09 (s, 3H), 1.63 – 
1.50 (m, 0H), 1.45 (s, 6H), 1.50 – 1.37 (m, 0H), 1.40 (s, 9H).
13
C 
NMR (101 MHz, CDCl3) δ  5 .79,  56. 6,  55.  ,  44.37, 
138.33, 133.90, 132.80, 132.28, 129.42, 127.02, 124.67, 117.52, 
86.43, 79.92, 49.37, 43.23, 40.92, 40.82, 31.27, 28.61, 28.36, 
25.60, 19.33, 17.97, 12.50. LC-MS (Linear gradient 5 → 95% 
MeCN, 0.1% TFA, 10 min): Rt (min): 7.18 (ESI-MS (m/z): 
669.02 (M+H
+
)). HRMS: calcd. for C30H44N4O7S3Na, 691.2246 
[M+Na
+
]; found 691.2235. 
Boc-Arg(Pbf)-Ψ[CH2SSO2-(p-Me)Ph] (18): Prepared 
according to general procedure 7 on a 0.383 mmol (404 mg) 
scale. Purified by automated column chromatography 2  →  0% 
EtOAc, pet-ether 40-60. Yield: 423 mg, 0.423 mmol, 55%. 
1
H 
NMR (400 MHz, CDCl3) δ 7.79 (d, J =  .4 Hz, 2H), 7.33 (d, J = 
8.1 Hz, 2H), 6.20 – 6.01 (m, 3H), 4.94 (d, J = 9.0 Hz, 1H), 3.83 – 
3.72 (m, 1H), 3.25 – 3.08 (m, 3H), 3.04 (dd, J = 13.7, 6.8 Hz, 
1H), 2.95 (s, 2H), 2.57 (s, 3H), 2.51 (s, 3H), 2.44 (s, 3H), 2.09 (s, 
3H), 1.63 – 1.47 (m, 4H), 1.45 (s, 6H), 1.40 (s, 9H). 
13
C NMR 
(101 MHz, CDCl3) δ  5 .92,  56.2 ,  45.25,  4 .64,  3 .5 , 
132.47, 130.14, 127.25, 124.78, 117.63, 86.54, 80.16, 49.33, 
43.38, 40.98, 40.85, 31.61, 31.60, 28.75, 28.50, 25.65, 21.81, 
19.44, 18.08, 12.63. LC-MS (Linear gradient 5 → 95% MeCN, 
0.1% TFA, 10 min): Rt (min): 7.33 (ESI-MS (m/z): 683.01 
(M+H
+
)). HRMS: calcd. for C31H46N4O7S3Na, 705.2421 
[M+Na
+
]; found 705.2402. 
Boc-Arg(Pbf)-Ψ[CH2SSO2-(p-OMe)Ph] (19): Prepared 
according to general procedure 7 on a 0.319 mmol (336 mg) 
scale. Purified by automated column chromatography 2  →   % 
EtOAc, pet-ether 40-60.  Yield: 142 mg, 0.212 mmol, 33%. 
1
H 
NMR (400 MHz, CDCl3) δ 7. 5 (d, J = 9.  Hz, 2H), 7.   (d, J = 
9.0 Hz, 2H), 6.16 – 5.97 (m, 3H), 4.92 (d, J = 9.0 Hz, 1H), 3.88 
(s, 3H), 3.85 – 3.73 (m, 1H), 3.29 – 3.08 (m, 3H), 3.04 (dd, J = 
13.8, 6.7 Hz, 1H), 2.95 (s, 2H), 2.57 (s, 3H), 2.51 (s, 3H), 2.09 (s, 
3H), 1.64 – 1.48 (m, 4H), 1.45 (s, 6H), 1.42 (s, 9H). 
13
C NMR 
(101 MHz, CDCl3) δ  63. 7,  5 .77,  56. 2,  3 .3 ,  32.35, 
129.49, 124.63, 117.49, 114.50, 86.40, 80.05, 55.81, 43.24, 
40.86, 40.64, 31.52, 28.61, 28.36, 25.47, 19.29, 17.93, 12.48. 
LC-MS (Linear gradient 5 → 95% MeCN,  . % TFA,    min): 
Rt (min): 7.18 (ESI-MS (m/z): 699.01 (M+H
+
)). HRMS: calcd. 
for C31H46N4O8S3Na, 721.2370 [M+Na
+
]; found 721.2341. 
Boc-Arg(Pbf)-Ψ[CH2SSO2-(p-NO2)Ph] (20): Prepared 
according to general procedure 7 0.337 mmol (355 mg) scale. 
Purified by automated column chromatography 2  →   % 
EtOAc, pet-ether 40-60. Yield: 172 mg, 0.241 mmol, 36%. 
1
H 
NMR (400 MHz, CDCl3) δ  .34 (d, J =  .9 Hz, 2H),  .   (d, J = 
8.5 Hz, 2H), 6.32 – 6.04 (m, 3H), 5.10 (d, J = 8.9 Hz, 1H), 3.83 – 
3.71 (m, 1H), 3.24 – 3.16 (m, 3H), 3.12 (dd, J = 13.6, 7.1 Hz, 
1H), 2.96 (s, 2H), 2.55 (s, 3H), 2.49 (s, 3H), 2.09 (s, 3H), 1.63 – 
1.48 (m, 4H), 1.46 (s, 6H), 1.38 (s, 9H). 
13
C NMR (101 MHz, 
CDCl3) δ  5 .96,  56. 5,  55.77,  5 .46,  49.4 ,  3 .32, 
132.44, 132.28, 128.34, 124.82, 124.71, 117.65, 86.57, 80.02, 
49.51, 43.19, 41.28, 40.80, 31.21, 28.60, 28.34, 25.69, 19.32, 
17.97, 12.49. LC-MS (Linear gradient 5 → 95% MeCN,  . % 
TFA, 10 min): Rt (min): 7.21 (ESI-MS (m/z): 713.99 (M
+
)). 
HRMS: calcd. for C30H43N5O9S3Na, 736.2115 [M+Na
+
]; found 
736.2095. 
Boc-Arg(Pbf)-Ψ[CH2SSO2-cHex] (22): Prepared according to 
general procedure 8 0.500 mmol (264 mg) scale. Purified by 
automated column chromatography 2  →    % EtOAc, pet-
ether 40-60. Yield: 96%. 
1
H NMR (400 MHz, CDCl3) δ 6.28 – 
6.06 (m, 3H), 5.12 (d, J = 8.9 Hz, 1H), 3.83 – 3.73 (m, 1H), 3.36 
– 3.05 (m, 5H), 2.96 (s, 2H), 2.57 (s, 3H), 2.51 (s, 3H), 2.31 – 
2.22 (m, 2H), 2.09 (s, 3H), 1.97 – 1.86 (m, 2H), 1.76 – 1.66 (m, 
1H), 1.64 – 1.49 (m, 6H), 1.46 (s, 6H), 1.42 (s, 9H), 1.37 – 1.16 
(m, 3H). 
13
C NMR (101 MHz, CDCl3) δ  5 .75,  56.23,  56.  , 
138.30, 132.87, 132.25, 124.64, 117.49, 86.41, 79.80, 71.27, 
50.15, 43.24, 41.09, 40.84, 31.56, 28.62, 28.39, 26.32, 26.17, 
25.71, 25.12, 25.06, 25.02, 19.33, 17.98, 12.50. LC-MS (Linear 
gradient 5 → 95% MeCN,  . % TFA,    min): Rt (min): 7.47 
(ESI-MS (m/z): 675.17 (M+H
+
)). HRMS: calcd. for 
C30H50N4O7S3Na, 697.2734 [M+Na
+
]; found 697.2709. 
4.1.4.  Backbone Synthes is   
Synthesis of phenyl alanine derived Urea 25 according to the 
literature procedure.
37
: step 1, Isocyanate formation: was 
achieved from the TFA salt TFA.H2N-Phe-OBn (17.2 g, 
48.7 mmol, 1.00 equiv.) and reaction progress was followed by 
TLC (5% MeOH/DCM). Step 2: Urea formation: according to 
the literature procedure.
37
 Reaction progress was followed by 
TLC (5% MeOH, DCM) and the title compound purified by 
column chromatography (  → 6% MeOH, DCM). Yield: (8.84 g, 
23.2  mmol, 48%). 
1
H NMR (400 MHz, CDCl3) δ 7.35 – 7.30 (m, 
3H), 7.30 – 7.26 (m, 2H), 7.21 – 7.17 (m, 3H), 7.02 – 6.97 (m, 
2H), 5.16 (d, J = 12.2 Hz, 1H), 5.07 (d, J = 12.2 Hz, 1H), 5.00 (d, 
J = 7.6 Hz, 1H), 4.82 (dt, J = 7.6, 5.9 Hz, 1H), 3.37 – 3.31 (m, 
4H), 3.09 (dd, J = 5.9, 3.1 Hz, 2H), 2.36 – 2.31 (m, 4H), 2.27 (s, 
3H). 
13
C NMR (101 MHz, CDCl3) δ  72.5 ,  56.47,  36. 3, 
135.23, 129.34, 128.55, 128.47, 128.43, 128.42, 126.91, 67.06, 
54.48, 54.38, 45.98, 43.56, 38.19. LC-MS (Linear gradient 5 → 
95% MeCN, 0.1% TFA, 40 min): Rt (min): 14.63 (ESI-MS 
(m/z): 382.04 (M+H
+
)).  
Carboxylic acid 26 was made according to the literature 
procedure.
37
: Benzyl ester 25 (8.84 g, 23.2 mmol, 1.00 equiv.) 
was dissolved in 1% AcOH / EtOH (250 mL) and 10wt. %  Pd/C 
(2.3 g) used. TLC (5% MeOH in DCM) confirmed reaction 
completion. Yield:  7.36 g, 25.3 mmol, quant. 
1
H NMR (400 
MHz, CDCl3) δ 7.   – 7.08 (m, 5H), 5.88 (s, 1H), 4.48 (dd, J = 
12.3, 6.4 Hz, 1H), 3.59 – 3.42 (m, 2H), 3.42 – 3.26 (m, 2H), 3.14 
(dd, J = 13.8, 5.0 Hz, 1H), 2.99 (dd, J = 13.8, 7.1 Hz, 1H), 2.73 – 
2.49 (m, 4H), 2.39 (s, 3H). 
13
C NMR (101 MHz, CDCl3) δ 
177.12, 156.91, 138.26, 129.71, 128.24, 126.60, 56.12, 53.09, 
43.96, 42.02, 38.18. 
4.1.5.  Coupl ing warheads  to  backbone  
Inhibitor HomoPhe-Ψ[CH2SSO2-Ph] (27): Prepared according 
to general procedure 9 on a 0.577 mmol (243 mg) scale. Purified 
  
by automated column chromatography 0 →   % MeOH, DCM.  
Yield: 281 mg, 0.472 mmol, 82%. To ensure high purity for 
biological testing an 82 mg portion was further purified by 
preparative HPLC (Linear gradient 5 → 95% MeCN,  . % TFA, 
80 min), returning 55 mg of the title compound as a TFA salt 
after lyophilisation which was > 98% pure by HPLC. 
1
H NMR 
(400 MHz, Methanol-d4) δ 7.9  (d, J =  .4 Hz, 2H), 7.7  – 7.63 
(m, 1H), 7.62 – 7.55 (m, 2H), 7.26 (d, J = 4.3 Hz, 4H), 7.23 – 
7.18 (m, 3H), 7.16 – 7.13 (m, 1H), 7.12 – 7.07 (m, 2H), 4.44 (dd, 
J = 9.0, 6.6 Hz, 1H), 4.21 – 4.06 (m, 2H), 4.01 – 3.91 (m, 1H), 
3.49 – 3.36 (m, 2H), 3.19 – 3.10 (m, 2H), 3.07 (dd, J = 13.7, 6.6 
Hz, 1H), 3.00 (dd, J = 6.4, 4.2 Hz, 2H), 2.92 (dd, J = 13.7, 9.0 
Hz, 1H), 2.95 – 2.80 (m, 2H), 2.84 (s, 3H), 2.65 – 2.56 (m, 1H), 
2.50 – 2.40 (m, 1H), 1.82 – 1.71 (m, 1H), 1.71 – 1.60 (m, 1H). 
13
C NMR (101 MHz, Methanol-d4) δ  74.63,  5 .5 ,  45.9 , 
142.54, 138.70, 135.16, 130.66, 130.38, 129.53, 129.46, 129.40, 
128.05, 127.82, 126.98, 57.98, 54.10, 49.38, 43.61, 42.38, 41.11, 
39.12, 36.22, 33.00. LC-MS (Linear gradient 5 → 95% MeCN, 
0.1% TFA, 40 min): Rt (min): 17.06 (ESI-MS (m/z): 595.13 
(M+H
+
)). HRMS: calcd. for C31H39N4O4S2, 595.2407 [M+H
+
]; 
found 595.2397. calcd. for C31H39N4O4S2Na, 617.2227 [M+Na
+
]; 
found 617.2214.  
Inhibitor HomoPhe-Ψ[CH2SSO2-(pMe)Ph] (28): Prepared 
according to general procedure 9 on a 0.485 mmol (211 mg) 
scale. Purified by automated column chromatography   →   % 
MeOH, DCM.   Yield: 297 mg, 0.488 mmol, Quant. To ensure 
high purity for biological testing a 33 mg portion was further 
purified by preparative HPLC (Linear gradient 5 → 95% MeCN, 
0.1% TFA, 80 min), returning 13 mg of the title compound as a 
TFA salt after lyophilisation which was > 99% pure by HPLC.  
1
H NMR (500 MHz, Methanol-d4) δ  . 9 (d, J =  .4 Hz,  H), 
7.79 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.1 Hz, 2H), 7.31 – 7.18 (m, 
6H), 7.15 (d, J = 7.5 Hz, 1H), 7.13 – 7.08 (m, 2H), 4.42 (dd, J = 
9.0, 6.6 Hz, 1H), 4.25 – 4.04 (m, 2H), 4.01 – 3.89 (m, 1H), 3.52 – 
3.35 (m, 2H), 3.21 – 3.07 (m, 2H), 3.03 (dd, J = 13.8, 6.7 Hz, 
1H), 2.98 (t, J = 6.6 Hz, 2H), 3.04 – 2.92 (m, 2H), 2.90 (dd, J = 
13.8, 9.0 Hz, 1H), 2.87 (s, 3H), 2.65 – 2.57 (m, 1H), 2.48 – 2.43 
(m, 1H), 2.42 (s, 3H), 1.81 – 1.73 (m, 1H), 1.69 – 1.60 (m, 1H). 
13
C NMR (126 MHz, Methanol-d4) δ  74.69,  5 .57,  46.63, 
143.29, 142.61, 138.71, 131.14, 130.38, 129.55, 129.45, 129.40, 
128.20, 127.84, 126.98, 57.95, 54.20, 43.65, 42.44, 41.10, 39.17, 
36.25, 33.05, 21.59. LC-MS (Linear gradient 5 → 95% MeCN, 
0.1% TFA, 40 min): Rt (min): 18.29 (ESI-MS (m/z): 609.10 
(M+H
+
)). HRMS: calcd. for C32H41N4O4S2, 609.2564 [M+H
+
]; 
found 609.2544. 
Inhibitor HomoPhe-Ψ[CH2SSO2-(p-OMe)Ph] (29): Prepared 
according to general procedure 9 on a 0.441 mmol (199 mg) 
scale . Purified by automated column chromatography   →   % 
MeOH, DCM.   Yield: 315 mg, 0.504 mmol, Quant. To ensure 
high purity for biological testing an 83 mg portion was further 
purified by preparative HPLC (Linear gradient 5 → 95% MeCN, 
0.1% TFA, 80 min),  returning 60 mg of the title compound as a 
TFA salt after lyophilisation which was > 99% pure by HPLC . 
1
H NMR (400 MHz, Methanol-d4) δ 7. 4 (d, J = 9.  Hz, 2H), 
7.28 – 7.18 (m, 7H), 7.16 – 7.05 (m, 5H), 4.43 (dd, J = 9.0, 6.5 
Hz, 1H), 4.23 – 4.04 (m, 2H), 4.00 – 3.91 (m, 1H), 3.86 (s, 3H), 
3.50 – 3.34 (m, 2H), 3.22 – 3.08 (m, 2H), 3.05 (dd, J = 13.7, 6.5 
Hz, 1H), 2.98 (t, J = 6.2 Hz, 2H), 3.05 – 2.90 (m, 2H), 2.91 (dd, J 
= 13.6, 9.0 Hz, 1H), 2.85 (s, 3H), 2.65 – 2.56 (m, 1H), 2.50 – 
2.40 (m, 1H), 1.83 – 1.72 (m, 1H), 1.71 – 1.59 (m, 1H). 
13
C NMR 
(101 MHz, Methanol-d4) δ  74.6 ,  65.47,  5 .54,  42.5 , 
138.72, 137.55, 130.56, 130.38, 129.53, 129.44, 129.39, 127.82, 
126.98, 115.65, 57.96, 56.42, 54.13, 43.62, 42.40, 41.02, 39.15, 
36.22, 33.04. LC-MS (Linear gradient 5 → 95% MeCN,  . % 
TFA, 40 min): Rt (min): 17.33 (ESI-MS (m/z): 625.11 (M+H
+
)). 
HRMS: calcd. for C32H41N4O5S2, 625.2513 [M+H
+
]; found 
625.2482, calcd. for C32H40N4O4S2Na, 647.2332 [M+Na
+
]; found 
647.2305. 
Inhibitor HomoPhe-Ψ[CH2SSO2-(p-NO2)Ph] (30): Prepared 
according to general procedure 9 on a 0.204 mmol (95 mg) scale. 
Purified by automated column chromatography   →   % MeOH, 
DCM.   Yield: 108 mg, 0.169 mmol, 83 %. To ensure high purity 
for biological testing all 108 mg was further purified by 
preparative HPLC (Linear gradient 5 → 95% MeCN,  . % TFA, 
80 min), returning 36 mg of the title compound as a TFA salt 
after lyophilisation which was > 98% pure by HPLC 
1
H NMR 
(400 MHz, Methanol-d4) δ  .36 (d, J = 9.  Hz, 2H),  .   (d, J = 
8.9 Hz, 2H), 7.32 – 7.15 (m, 7H), 7.13 – 7.04 (m, 3H), 4.42 (dd, J 
= 8.8, 6.8 Hz, 1H), 4.23 – 4.07 (m, 2H), 3.87 – 3.77 (m, 1H), 
3.51 – 3.36 (m, 2H), 3.22 – 3.09 (m, 2H), 3.09 – 3.01 (m, 3H), 
3.17 – 2.86 (m, 2H), 2.92 (dd, J = 13.7, 8.8 Hz, 1H), 2.86 (s, 3H), 
2.66 – 2.57 (m, 1H), 2.50 – 2.39 (m, 1H), 1.80 – 1.70 (m, 1H), 
1.68 – 1.57 (m, 1H). 
13
C NMR (101 MHz, Methanol-d4) δ 
174.72, 158.55, 151.94, 151.01, 142.37, 138.65, 130.37, 129.58, 
129.47, 129.46, 129.35, 127.87, 127.00, 125.89, 57.93, 54.15, 
43.63, 42.42, 41.73, 39.10, 36.14, 32.84. LC-MS (Linear gradient 
5 → 95% MeCN,  . % TFA, 4  min): Rt (min):  7.55 (ESI-MS 
(m/z): 640.11 (M+H
+
)). HRMS: calcd. for C31H38N5O6S2, 
640.2258 [M+H
+
]; found 640.2232.  
 Inhibitor HomoPhe-Ψ[CH2SSO2-cHex] (36): Prepared 
according to general procedure 9 on a 0.391 mmol (167 mg) 
scale. Purified by automated column chromatography   →    % 
MeOH, DCM.   Yield: 163 mg, 0.271 mmol, 69 %. To ensure 
high purity for biological testing all 163 mg was further purified 
by preparative HPLC (Linear gradient 5 → 95% MeCN,  . % 
TFA, 80 min), returning 130 mg of the title compound as a TFA 
salt after lyophilisation which was > 99% pure by HPLC 
1
H 
NMR (400 MHz, Methanol-d4) δ  . 5 (d, J =  .5 Hz,  H), 7.34 – 
7.10 (m, 10H), 4.48 (dd, J = 9.2, 6.2 Hz, 1H), 4.27 – 4.08 (m, 
2H), 4.08 – 3.96 (m, 1H), 3.52 – 3.34 (m, 2H), 3.26 (tt, J = 11.7, 
3.4 Hz, 1H), 3.23 – 3.05 (m, 5H), 3.07 – 2.86 (m, 2H), 2.96 (dd, J 
= 13.8, 9.3 Hz, 1H), 2.86 (s, 3H), 2.71 (ddd, J = 14.4, 9.3, 5.4 Hz, 
1H), 2.59 (ddd, J = 13.7, 9.1, 7.0 Hz, 1H), 2.26 – 2.14 (m, 2H), 
1.94 – 1.84 (m, 3H), 1.84 – 1.74 (m, 1H), 1.73 – 1.66 (m, 1H), 
1.55 – 1.43 (m, 2H), 1.42 – 1.27 (m, 2H), 1.22 (tt, J = 12.6, 3.2 
Hz, 1H). 
13
C NMR (101 MHz, Methanol-d4) δ  74.76,  5 .59, 
142.66, 138.84, 130.37, 129.57, 129.55, 129.43, 127.80, 127.03, 
71.85, 58.00, 54.17, 50.14, 43.63, 42.44, 41.37, 39.17, 36.65, 
33.03, 27.51, 27.45, 26.23, 26.11, 26.07. LC-MS (Linear gradient 
5 → 95% MeCN,  . % TFA, 4  min): Rt (min):  7.97 (ESI-MS 
(m/z): 601.08 (M+H
+
)). HRMS: calcd. for C31H45N4O4S2, 
601.2877 [M+H
+
]; found 601.2859, calcd. for C31H44N4O4S2Na, 
623.2696 [M+Na
+
]; found 623.2672.  
Inhibitor Arg-Ψ[CH2SSO2-Ph] (31): Prepared according to 
general procedure 10 on a 0.190 mmol (127 mg) scale. 
Purification directly by preparative HPLC (Linear gradient 5 → 
40% MeCN, 0.1% TFA, 80 min) returned the title compound as a 
TFA salt after lyophilisation which was >99% pure by HPLC: 
Yield: 131 mg, 0.167 mmol, 88%. 
1
H NMR (400 MHz, 
Methanol-d4) δ  . 5 (d, J =  .7 Hz,  H), 7.9  – 7.93 (m, 2H), 
7.77 – 7.70 (m, 1H), 7.69 – 7.61 (m, 2H), 7.27 – 7.15 (m, 5H), 
4.33 (dd, J = 9.0, 6.6 Hz, 1H), 4.20 – 4.03 (m, 2H), 4.06 – 3.94 
(m, 2H), 3.55 – 3.32 (m, 2H), 3.15 – 3.01 (m, 5H), 2.97 – 2.92 
(m, 3H), 2.88 (s, 3H), 1.69 – 1.34 (m, 4H). 
13
C NMR (101 MHz, 
Methanol-d4) δ 174.99, 158.64, 158.56, 145.98, 138.64, 135.26, 
130.75, 130.34, 129.56, 128.16, 127.88, 58.21, 54.13, 43.63, 
42.40, 41.94, 40.93, 39.03, 31.39, 26.23. LC-MS (Linear gradient 
5 → 95% MeCN,  . % TFA, 4  min): Rt (min):  2.24 (ESI-MS 
  
(m/z): 590.33 (M+H
+
)). HRMS: calcd. for C27H40N7O4S2, 
590.2578 [M+H
+
]; found 590.2557.  
Inhibitor Arg-Ψ[CH2SSO2-(pMe)Ph] (32): Prepared according 
to general procedure 10 on a 0.180 mmol (124 mg) scale yielding 
254 mg of crude material.   Purification of a 44 mg portion of 
crude material directly by preparative HPLC (Linear gradient 5 
→ 4 % MeCN,  . % TFA,    min) gave the title compound as a 
TFA salt after lyophilisation which was >99% pure by HPLC: 
Yield: 20 mg, (0.152 mmol, 84%, assuming all crude was to be 
purified). 
1
H NMR (500 MHz, Methanol-d4) δ  . 3 (d, J =  .7 
Hz, 1H), 7.82 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 7.28 – 
7.17 (m, 5H), 4.33 (dd, J = 9.1, 6.6 Hz, 1H), 4.29 – 3.83 (m, 2H), 
4.06 – 3.94 (m, 1H), 3.59 – 3.21 (m, 2H), 3.15 – 3.00 (m, 3H), 
2.98 – 2.89 (m, 3H), 2.88 (s, 3H), 2.45 (s, 3H), 1.69 – 1.60 (m, 
1H), 1.61 – 1.49 (m, 2H), 1.46 – 1.38 (m, 1H). 
13
C NMR (126 
MHz, Methanol-d4) δ  74.9 ,  5 .64,  5 .57,  46.77,  43. 6, 
138.66, 131.20, 130.34, 129.56, 128.27, 127.87, 58.21, 54.13, 
43.64, 42.40, 41.95, 40.90, 39.04, 31.43, 26.24, 21.59. LC-MS 
(Linear gradient 5 → 95% MeCN,  . % TFA, 4  min): Rt (min): 
13.70 (ESI-MS (m/z): 604.33 (M+H
+
)). HRMS: calcd. for 
C28H42N7O4S2, 604.2734 [M+H
+
]; found 604.2717.  
Inhibitor Arg-Ψ[CH2SSO2-(p-OMe)Ph] (33): Prepared 
according to general procedure 10 on a 0.094 mmol (66 mg) 
scale.   Purification by preparative HPLC (Linear gradient 5 → 
40% MeCN, 0.1% TFA, 80 min) gave the title compound as a 
TFA salt after lyophilisation which was >99% pure by HPLC: 
Yield: 50 mg, 0.61 mmol, 65%. 
1
H NMR (400 MHz, Methanol-
d4) δ  . 5 (d, J =  .7 Hz,  H), 7.   (d, J = 8.9 Hz, 2H), 7.45 – 
7.18 (m, 5H), 7.13 (d, J = 8.9 Hz, 2H), 4.33 (dd, J = 9.1, 6.5 Hz, 
1H), 4.20 – 4.05 (m, 2H), 4.03 – 3.94 (m, 1H), 3.89 (s, 3H), 3.54 
– 3.35 (m, 2H), 3.24 – 3.00 (m, 5H), 2.99 – 2.89 (m, 3H), 2.88 (s, 
3H), 1.69 – 1.48 (m, 3H), 1.47 – 1.37 (m, 1H). 
13
C NMR (101 
MHz, Methanol-d4) δ  75.  ,  65.56,  5 .6 ,  5 .54,  3 .6 , 
137.43, 130.66, 130.34, 129.54, 127.85, 115.70, 58.27, 56.45, 
54.09, 49.02, 43.62, 42.37, 41.93, 40.87, 39.00, 31.46, 26.23. 
LC-MS (Linear gradient 5 → 95% MeCN,  . % TFA, 4  min): 
Rt (min): 12.88 (ESI-MS (m/z): 620.25 (M+H
+
)). HRMS: calcd. 
for C28H42N7O5S2, 620.2683 [M+H
+
]; found 620.2656.  
Inhibitor Arg-Ψ[CH2SSO2-(p-NO2)Ph] (34): Prepared 
according to general procedure 10 on a 0.217 mmol (155 mg) 
scale. Purified by reverse phase automated column 
chromatography (Linear gradient 5 → 4 % MeCN,  . % TFA, 
40 min) using a Biotage
®
 SNAP Ultra C18, 60 g column yielding 
the title compound as a TFA salt after lyophilisation which was 
>98% pure by HPLC. Yield: 110 mg, 0.132 mmol, 61%. 
1
H 
NMR (400 MHz, Methanol-d4) δ  .47 (d, J =  .5 Hz, 2H), 8.19 
(d, J = 8.5 Hz, 2H), 8.10 (d, J = 8.7 Hz, 1H), 7.31 – 7.17 (m, 5H), 
4.33 (dd, J = 9.2, 6.4 Hz, 1H), 4.21 – 4.02 (m, 2H), 4.00 – 3.90 
(m, 1H), 3.45 (br s, 2H), 3.22 – 2.98 (m, 7H), 2.95 – 2.90 (m, 
1H), 2.98 – 2.80 (m, 2H), 2.88 (s, 3H), 1.69 – 1.40 (m, 4H). 
13
C 
NMR (101 MHz, Methanol-d4) δ  75.  ,  5 .6 ,  5 .54,  52. 9, 
150.82, 138.65, 130.30, 129.62, 129.56, 127.86, 125.97, 58.21, 
54.08, 43.62, 42.36, 41.89, 41.42, 38.93, 31.52, 26.22. LC-MS 
(Linear gradient 5 → 95% MeCN,  . % TFA, 4  min): Rt (min): 
13.24 (ESI-MS (m/z): 635.33 (M+H
+
)). HRMS: calcd. for 
C27H39N8O6S2, 635.2428 [M+H
+
]; found 635.2407. 
Inhibitor Arg-Ψ[CH2SSO2-cHex] (35): Prepared according to 
general procedure 10 on a 0.220 mmol (148 mg) scale. 
Purification directly by preparative HPLC (Linear gradient 5 → 
40% MeCN, 0.1% TFA, 80 min) returned the title compound as a 
TFA salt after lyophilisation which was >99% pure by HPLC 
Yield: 93 mg, 0.118 mmol, 54%. 
1
H NMR (400 MHz, Methanol-
d4) δ  .   (d, J =  .  Hz,  H), 7.34 – 7.19 (m, 5H), 4.40 (dd, J = 
9.6, 5.9 Hz, 1H), 4.18 – 4.02 (m, 3H), 3.51 – 3.38 (m, 2H), 3.32 
(tt, J = 11.8, 3.4 Hz, 1H), 3.25 – 3.04 (m, 7H), 2.96 (dd, J = 13.8, 
9.6 Hz, 1H), 2.87 (s, 3H), 2.29 – 2.20 (m, 2H), 1.95 – 1.88 (m, 
2H), 1.75 – 1.59 (m, 4H), 1.59 – 1.46 (m, 3H), 1.46 – 1.31 (m, 
2H), 1.29 – 1.19 (m, 1H). 
13
C NMR (101 MHz, Methanol-d4) δ 
175.17, 158.63, 158.59, 138.84, 130.32, 129.55, 127.81, 71.96, 
58.29, 54.10, 50.12, 42.37, 42.00, 41.29, 39.02, 31.87, 27.57, 
27.43, 26.32, 26.22, 26.09, 26.05. LC-MS (Linear gradient 5 → 
95% MeCN, 0.1% TFA, 40 min): Rt (min): 13.65 (ESI-MS 
(m/z): 596.33 (M+H
+
)). HRMS: calcd. for C27H46N7O4S2, 
596.3047 [M+H
+
]; found 596.3028. 
4.2. Biology 
4 .2.1.  Papain  Assay  
4 .2.1.1.  Materials  
All tested inhibitors were prepared as described and were >98% 
pure as determined by analytical HPLC (chromatograms in 
Supporting Information). Papain from papaya latex was 
purchased as a lyophilised powder from Sigma Aldrich
®
. The 
substrate Nα-Benzoyl-L-arginine 4-nitroanilide hydrochloride 
was purchased from Sigma Aldrich
®
. As assay buffer sodium 
phosphate (100 mM, pH 6.5) containing EDTA (1.5 mM) was 
used. Compounds were dissolved in DMSO (for molecular 
biology grade) which was purchased from Sigma Aldrich
®
. 
A CLARIOstar microplate reader with Corning
®
 96 well UV- 
transparent plates was used. 
4.2.1.2.  Method 
Each inhibitor was screened by three separate experiments, 
each conducted in duplicate. The thiol independent papain assay 
was based on our previously reported assay.
48
 Papain stock 
solution was prepared in assay buffer (40  M), the solution 
shaken for 10 min. and then centrifuged at 13,200 rpm for 3 min. 
The substrate stock solution (Bz-L-Arg-pNA) was prepared in 
DMSO (50 mM).  
Stock solutions of inhibitors were prepared in DMSO 
(9.8 mM) and a 1:1 dilution made with buffer solution 
(4.95 mM), from which relevant serial dilutions with 1:1 
DMSO:Buffer solution were made to achieve the desired 
concentrations of inhibitor solutions for the assay. 
 To each well was added inhibitor solution (4.0  L), buffer 
solution ( 72.   L) and papain solution (2 .   L) followed by 
thorough mixing (15 times by pipette upon papain addition). For 
the positive control a DMSO/buffer solution (1:1) was used 
instead of the inhibitor solution and the negative control (blank) 
was taken by replacing papain solution with assay buffer. After 
1 h incubation with shaking (shaker plate set to 100 rpm) a 
sample (98.0  L) was taken from each well and added to wells 
containing substrate solution (2.0  L), Mixed thoroughly by 
pipette (15 times), the plate covered with a lid and centrifuged at 
1000 rpm for 1 min (to remove any air bubbles) and the 
subsequent liberation of p-nitroaniline was measured over a 1h. 
time frame with 1 measurement per well per minute. Final 
concentrations in the wells were: enzyme: 4  M; substrate: 
1.0 mM; inhibitor: Doubling dilution range starting at 10  M 
giving: 10  M, 5  M, 2.5  M,  .25  M,  .625  M,  .3 25  M, 
156.25 nM, 78.125 nM, 39.0625 nM. 
Processing: As the liberation of p-nitro anilide was linear, the 
response was measured by applying a line of best fit to the blank 
corrected data and taking the gradient as a measure of the 
response. The gradients were normalized against the gradient of 
the positive control (100% response in the absence of inhibitor). 
The normalized response was used to calculate the IC50 value by 
  
plotting log(inhibitor) vs. normalized response with the 
GraphPad Prism software suite.  
4.2.2.  S.  mansoni  bio-assay 
4 .2.2.1.  Preparat ion  o f  schis tosomula  
S. mansoni life cycle is maintained at the Institute of Tropical 
Medicine, University Hospital Tübingen/Germany. S. mansoni 
infected vector snails were exposed to day-light to induce 
shedding of cercariae. Schistosomula were obtained by 
mechanical transformation of cercariae by vortexing following 
published procedures.
46
 Schistosomula were kept in 48-well 
plates in schistosomula culture medium (SCM; phenol-red free 
medium 199 [M199; catalog number 11043-023; Gibco], 5.5 mM 
d-glucose, 200 U/ml penicillin, 200  g/ml streptomycin, 1% 
heat-inactivated FCS [iFCS]) at 400 schistosomula/1 ml 
SCM/well for 24 h to allow maturation before being further 
processed. 
4.2.2.2.  Schis tosomula  in  v i t ro drug suscept ib i l i ty  
assay  
All compounds were tested in vitro against mature 
schistosomula. Thiosulfonate compounds were dissolved in 
DMSO at a stock concentration of 10 mM. Mefloquine 
hydrochloride (MQ, Sigma-Aldrich) and auranofin (AU, Sigma-
Aldrich) were dissolved in DMSO at 36 mM and 14.7 mM, 
respectively. All compounds were stored at -20°C until further 
use. 96 well, sterile, flat bottom plates were predosed with 
compounds at respective concentrations. Drug dilutions were 
done in SCM. Schistosomula were distributed at a density of 100 
worms/well. The number of worms was counted for each 
individual well. Final volume/well was 225 µl. In vitro cultures 
were kept at 37°C and 5% CO2. Each experiment included MQ 
and AU to control for schistosomula inhibition. Worm viability 
during in vitro culture was controlled using ‘medium only’ and 
DMSO (1%), respectively.  
After the described incubation time (1 day, 3 days or 7 days) 
the viability of worms per drug concentration was analysed by an 
inverted microscope (Nikon Eclipse Ti) using 40x magnification. 
On the basis of motility and morphology, the parasites were 
classified as viable (movement and normal appearance) or dead 
(no movement within 10 s and/or severe morphological changes 
of any kind compared to the morphology of untreated parasites, 
e.g., granularity, blebbing). 
Data analysis: Viability of schistosomula is reported as the 
proportion of viable schistosomula to the total number of 
schistosomula per respective well. Viability in % and log 
concentration of the drug were used to estimate the IC50 by 
GraphPad Prim 6 applying the built-in 4 parametric regression 
analysis to model curve fit.  
 
4.3. Stability tests of thiosulfonate inhibitors 
All stability tests were carried out in 0.1 M sodium phosphate 
buffer of the corresponding pH with Ac-Phe-OH used as an 
internal standard. 70  L of Ac-Phe-OH solution (1 mg/mL, 
0.07 mg) in phosphate buffer of the relevant pH was added to 
25  L of inhibitor solution (9.8 mM stock solution in DMSO) 
and diluted with 880  L of pH buffer solution giving a final 
volume of 1 mL with 5% DMSO. The sample was shaken for 
10 min. before being centrifuged at 13,200 rpm for 5 min. and 
transferred to an HPLC vial for sampling. The sample was then 
analysed over 12 hrs. by HPLC using 12 × 60 min. gradients 
from (5 → 95% MeCN, 0.1% TFA, 60 min.) yielding 12 
measurements 1 h apart, a blank sample containing 5% DMSO in 
phosphate buffer was run after the analysis for subtraction from 
the baseline. The Inhibitor peak was integrated against the 
internal standard, data normalised to show percentage 
degradation with time and plotted on a scatter graph for 
visualisation.  
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